Purpose: A potential application of hematopoietic growth factors is to obtain an increased dose-intensity. This can be achieved by either higher doses of chemotherapy with standard intervals, or by standard doses with shorter intervals. The potential of these approaches has not been investigated systematically.
Patients And Methods: In a randomized, multicenter study, 49 advanced breast cancer patients were treated with granulocyte colony-stimulating factor (G-CSF) and either increasing doses of epirubicin and cyclophosphamide with fixed intervals (arm one) or progressively shorter intervals with fixed doses of epirubicin and cyclophosphamide (arm two). A cohort of at least six patients was studied at each interval/dose. A more intensified interval/dose was given if less than 50% of patients encountered a dose-intensity limiting criterium (DILC) in the first three courses.
Results: In arm one, epirubicin 140 mg/m2 and cyclophosphamide 800 mg/m2 every 21 days was too toxic. Subsequently, epirubicin 120 mg/m2 and cyclophosphamide 700 mg/m2 was tested with two of 10 patients encountering a DILC. All initial DILCs consisted of febrile neutropenia. In arm two, epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2 could be administered safely with 14- and 12-day intervals. In the 10-day interval, eight of 12 patients completed the first three cycles without a DILC. In the 8-day interval, seven of eight patients encountered a DILC. Incomplete neutrophil recovery, and to a lesser extent stomatitis, were dose-limiting.
Conclusion: In combination with G-CSF, epirubicin 120 mg/m2 and cyclophosphamide 700 mg/m2 every 21 days was feasible (projected dose-intensity, 40 mg/m2/wk and 233 mg/m2/wk, respectively). Epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2 could be administered safely every 10 days, allowing a projected dose-intensity of 52.5 mg/m2/wk and 350 mg/m2/wk, respectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.1997.15.4.1367 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
JAMA
December 2024
Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai.
Article Synopsis
- The study focuses on assessing the effectiveness and side effects of combining camrelizumab, an anti-PD-1 antibody, with chemotherapy for patients with early or locally advanced triple-negative breast cancer.
- The phase 3 trial involved 441 patients from various hospitals in China, where they were randomly assigned to receive either camrelizumab or a placebo along with standard chemotherapy over several weeks.
- Results showed a higher rate of pathological complete response—meaning no invasive tumors were detected—in the camrelizumab group (56.8%) compared to the placebo group (44.7%), indicating camrelizumab may enhance the effectiveness of chemotherapy.
Clinicopathological factors affecting response and survival in stage III breast cancer patients undergoing a dose-dense neoadjuvant regimen.
Clin Ter
November 2024
Department of Physiology, Hanoi Medical University, Hanoi, Vietnam.
Introduction: Identifying predictors of pathological complete response (pCR) and long-term outcomes after neoadjuvant treatment for breast cancer is needed to individualize treatment and patient monitoring. This study aimed to investigate clinicopathological factors affecting pCR and long-term outcomes in stage III breast cancer patients receiving a dose-dense neoadjuvant regimen.
Methods: This is a retrospective study including patients with stage III breast cancer who received neoadjuvant chemotherapy consisting of doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m², followed by paclitaxel 175 mg/m² every two weeks at Vietnam National Cancer Hospital and Hanoi Oncology Hospital between January 2015 and December 2022.
Background: Idiopathic retroperitoneal fibrosis is characterized by the development of inflammatory infiltrates with marked fibrosis along the large retroperitoneal vessels. Rituximab in combination with glucocorticoids constitute an effective therapy, but the responses are not long-lasting. In other similar situations, addition of cyclophosphamide to the combination achieved longer and deeper responses.
View Article and Find Full Text PDFImportance: The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines.
Objective: To evaluate whether the addition of lenvatinib to IE (LEN-IE) improves outcomes in children and young adults with relapsed or refractory osteosarcoma.
Design, Setting, And Participants: The OLIE phase II, open-label, randomized clinical trial was conducted globally across Europe, Asia and the Pacific, and North America.
Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC).
BMC Cancer
October 2024
Breast Cancer Center, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Article Synopsis
- Anlotinib, a tyrosine kinase inhibitor, was studied for its effectiveness and safety when combined with a chemotherapy regimen (docetaxel, epirubicin, and cyclophosphamide) as neoadjuvant treatment for locally advanced triple-negative breast cancer (TNBC).
- The study involved 18 patients who received an average of nearly six treatment cycles; results showed a high overall response rate of 83.33% and a complete pathological response of 55.6%, indicating significant tumor reduction.
- The treatment had manageable side effects, with 27.8% of patients experiencing severe adverse events, but no participants had to stop treatment due to these effects, suggesting the combined regimen is worth further investigation
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!